A cost‐effectiveness analysis of behavioural, pharmacological, and surgical obesity treatments in Canada
RYGB and HBI are cost-effective for managing class III obesity. While RYGB provided the greatest health gains, access remains limited. Neither pharmacotherapy was cost-effective at current prices. Lower drug prices could significantly improve pharmacotherapy cost-effectiveness.
Authors
- Jeromie Ballreich (ORCID: https://orcid.org/0000-0003-2564-4577)
- Vanessa Tardio (ORCID: https://orcid.org/0009-0003-7841-1619)
- Nisha J. Gupta (ORCID: https://orcid.org/0000-0002-8799-1171)
- Kaberi Dasgupta (ORCID: https://orcid.org/0000-0002-2447-3553)
- Areni Chorbajian
- Allie Babyak
Institutions
- Johns Hopkins University (US)
- McGill University Health Centre (CA)
- McGill University (CA)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-07-21
- DOI
- https://doi.org/10.1111/dom.16627
- Citations
- 2
- Primary Topic
- Pharmacology and Obesity Treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.79